|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||146.93 - 147.40|
|52-week range||146.93 - 147.40|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||0.21|
|Earnings date||09 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss news that Abbvie’s Humira drug now faces competition.
NORTH CHICAGO, Ill. & EXTON, Pa., January 06, 2023--AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
Health care reporter Anjalee Khemlani outlines how inflation and supply and demand issues are putting the squeeze on AbbVie's Botox treatments.